| T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production JC Riches, JK Davies, F McClanahan, R Fatah, S Iqbal, S Agrawal, ... Blood, The Journal of the American Society of Hematology 121 (9), 1612-1621, 2013 | 568 | 2013 |
| PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia F McClanahan, B Hanna, S Miller, AJ Clear, P Lichter, JG Gribben, ... Blood, The Journal of the American Society of Hematology 126 (2), 203-211, 2015 | 210 | 2015 |
| Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with … J Hillengass, T Bäuerle, R Bartl, M Andrulis, F McClanahan, FB Laun, ... British journal of haematology 153 (6), 721-728, 2011 | 176 | 2011 |
| The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia SEM Herman, A Montraveta, CU Niemann, H Mora-Jensen, M Gulrajani, ... Clinical Cancer Research 23 (11), 2831-2841, 2017 | 157 | 2017 |
| Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo BS Hanna, F McClanahan, H Yazdanparast, N Zaborsky, V Kalter, ... Leukemia 30 (3), 570-579, 2016 | 137 | 2016 |
| RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics E Salzer, D Cagdas, M Hons, EM Mace, W Garncarz, ÖY Petronczki, ... Nature immunology 17 (12), 1352-1360, 2016 | 130 | 2016 |
| Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model F McClanahan, JC Riches, S Miller, WP Day, E Kotsiou, D Neuberg, ... Blood, The Journal of the American Society of Hematology 126 (2), 212-221, 2015 | 118 | 2015 |
| Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations JC Riches, CJ O’Donovan, SJ Kingdon, F McClanahan, AJ Clear, ... Blood, The Journal of the American Society of Hematology 123 (26), 4101-4110, 2014 | 106 | 2014 |
| Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies KA Rogers, L Mousa, Q Zhao, SA Bhat, JC Byrd, Z El Boghdadly, ... Leukemia 33 (10), 2527-2530, 2019 | 78 | 2019 |
| Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6 M Witzens-Harig, D Hose, S Jünger, C Pfirschke, N Khandelwal, ... Blood, The Journal of the American Society of Hematology 121 (22), 4493-4503, 2013 | 52 | 2013 |
| Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients A Heilgeist, F McClanahan, AD Ho, M Witzens‐Harig Cancer 119 (1), 99-106, 2013 | 52 | 2013 |
| Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations F Lucas, K Larkin, CT Gregory, S Orwick, TJ Doong, A Lozanski, ... Blood, The Journal of the American Society of Hematology 135 (24), 2192-2195, 2020 | 48 | 2020 |
| Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals J Hillengass, B Stieltjes, T Bäuerle, F McClanahan, C Heiss, T Hielscher, ... Acta Radiologica 52 (3), 324-330, 2011 | 43 | 2011 |
| T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma F Lucas, M Pennell, Y Huang, DM Benson, YA Efebera, M Chaudhry, ... Biology of Blood and Marrow Transplantation 26 (1), 7-15, 2020 | 42 | 2020 |
| Inhibiting Bruton’s tyrosine kinase in CLL and other B-cell malignancies F Lucas, JA Woyach Targeted oncology 14, 125-138, 2019 | 39 | 2019 |
| Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial P Dreger, H Döhner, F McClanahan, R Busch, M Ritgen, H Greinix, ... Blood, The Journal of the American Society of Hematology 119 (21), 4851-4859, 2012 | 34 | 2012 |
| Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin C Dürr, BS Hanna, A Schulz, F Lucas, M Zucknick, A Benner, A Clear, ... haematologica 103 (4), 688, 2018 | 33 | 2018 |
| Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD 2002 prospective multicentre randomized phase III trial M Witzens‐Harig, A Benner, F McClanahan, J Klemmer, J Brandt, ... British journal of haematology 171 (5), 710-719, 2015 | 32 | 2015 |
| Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active JS Garcia, HT Kim, HM Murdock, CS Cutler, J Brock, M Gooptu, VT Ho, ... Blood Advances 5 (24), 5536-5545, 2021 | 29 | 2021 |
| Long‐term population‐based risks of breast cancer after childhood cancer RC Reulen, AJ Taylor, DL Winter, CA Stiller, C Frobisher, ER Lancashire, ... International journal of cancer 123 (9), 2156-2163, 2008 | 26 | 2008 |
John GribbenProfessor of Medical Oncology, Queen Mary University of LondonVerified email at qmul.ac.uk
